What is ALNY stock price today?

ALNY (Alnylam Pharmaceuticals Inc) stock is trading at $333.39 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ALNY stock going up or down today?

ALNY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ALNY stock now?

The decision to buy ALNY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ALNY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ALNY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ALNY stock overvalued or undervalued?

ALNY currently trades at a P/E ratio of 145.05, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if ALNY is fairly priced.

What is ALNY's P/E ratio?

ALNY has a price-to-earnings (P/E) ratio of 145.05, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ALNY's market cap?

ALNY (Alnylam Pharmaceuticals Inc) has a market capitalization of $45.01 billion, making it a mid-cap stock.

What is ALNY's price to book ratio?

ALNY trades at a price-to-book (P/B) ratio of 56.30, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ALNY pay dividends?

ALNY does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ALNY's dividend yield?

ALNY does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ALNY stock a good long-term investment?

ALNY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ALNY's revenue growth rate?

ALNY has shown revenue growth of 0.8% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, ALNY is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in ALNY?

Key risks for ALNY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ALNY compare to its competitors?

Compare ALNY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ALNY's performance and positioning.

What is ALNY's stock price target for 2026?

Our AI model provides price targets for ALNY based on fundamental analysis: Bull case $433.41 (+30%), Base case $383.40 (+15%), Bear case $300.05 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ALNY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ALNY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ALNY's next earnings report?

ALNY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ALNY - Alnylam Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$333.39

$-6.02 (-1.77%)

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Key Statistics

Market Cap

$45.01B

P/E Ratio

145.05

P/B Ratio

56.30

EPS

$2.34

Revenue Growth

+0.8%

Profit Margin

0.1%

Employees

2,500

How ALNY Compares to Peers

ALNY trades at a premium valuation vs peers (highest P/E)

ALNY has the fastest revenue growth among competitors

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ALNY(This stock)	$45.01B	145.0	1%	0.1%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.50B	20.5	-0%	0.1%	vs BIIB

Alnylam Pharmaceuticals Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.alnylam.com
Sector: Health Care
Industry: Biotechnology

ALNY - Alnylam Pharmaceuticals Inc

About Alnylam Pharmaceuticals Inc

ALNY Key Statistics

How ALNY Compares to Peers

Alnylam Pharmaceuticals Inc Company Information

ALNY Lician Score

ALNY Financial Snowflake

Upcoming Events for ALNY